Catalent acquires Juniper Pharmaceuticals


The acquisition will strengthen the technology providers offerings in formulation development and oral dose manufacturing

Catalent has successfully completed a previously announced tender offer for all of the outstanding shares of common stock of Juniper Pharmaceuticals.

Catalent is a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.

The acquisition of Juniper expands and strengthens Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing. The move will also complement its integrated global clinical and commercial supply network.

Sign up for your free email newsletter

Catalent will acquire Juniper at a price of $11.50 per share net, to the seller in cash without interest, but subject to and reduced by any required withholding of taxes.